期刊文献+

阿托伐他汀对自发性高血压大鼠HMG-CoA还原酶表达的影响 被引量:2

Effect of atorvastatin on HMG-CoA reductase expression in spontaneously hypertensive rats
下载PDF
导出
摘要 目的:评价阿托伐他汀对自发性高血压大鼠(SHR)HMG-CoA还原酶表达的影响。方法:12只8周龄的SHR随机分为蒸馏水饲养组(SHRDW组,n=6)与阿托伐他汀治疗组(SHRATV组,n=6),并以6只同周龄的正常血压大鼠(WKY)作为对照(WKY组,n=6)。采用RT-PCR与Westernblotting法分别检测HMG-CoA还原酶的mRNA及蛋白表达。同时检测血压与血脂。结果:给药10周后,SHRATV组收缩压显著低于治疗前及SHRDW组(P<0.05),其血清TC、TG、LDL-C及HDL-C的水平与SHRDW组及WKY组相比,也明显降低(P<0.05);SHRATV组HMG-CoA还原酶mRNA的表达水平在给药10周后显著低于WKY组及SHRDW组(P<0.05),其蛋白表达水平同样出现类似的结果。结论:阿托伐他汀能够下调HMG-CoA还原酶的mRNA及蛋白表达水平,不仅使SHR的血脂降低,在某种程度上,还可能与其血压的下降有关。 AIM: To evaluate the effect of atorvastatin on HMG- CoA reductase (HMGR) expression level in spontaneously hypertensive rats (SHR). METHODS: Twelve eight- week- old SHR was randomized into distilled water group ( SHRDW group, n = 6) and atorvastatin - treated group ( SHRATV group, n = 6). The age - matched Wistar - Kyoto rats (WKY) were used as control (WKY group, n=6). RT-PCR and Western blotting were used to detect HMGR mRNA and protein expression levels; respectively. Meanwhile, systolic blood pressure (SBP) and serum lipid levels were examined. RESULTS: Ten weeks a treatment, SBP in SHRATV group was markedly decreased compared with before treatment and SHRDW group (P 〈0. 05). The levels of TC, TG, LDL- C and HDL- C in SHRAw group were also markedly lower than those in SHRDW group and WKYgroup (P 〈0. 05). 10 weeks later, HMGR mRNA levels decreased markedly in SHRAw group compared to WKY group andSHRDW group (P 〈0. 05). The similar results were found in HMGR protein expression levels. CONCLUSIONS: Atorvastatin downregulates mRNA and protein expression levels of HMGR in SHR, which not only decreases the serum lipids levels, but also impacts blood pressure to a certain extent.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2007年第1期44-48,共5页 Chinese Journal of Pathophysiology
基金 国家自然科学基金资助项目(No.30470715)
关键词 阿托伐他汀 HMG—CoA还原酶 高血压 大鼠 Atorvastatin HMG-CoA reductuse Hypertension Rats
  • 相关文献

参考文献11

  • 1Ginsberg HN, Update on the treatment of hypercholestelemia, with focus on HMG- CoA reductase inhibitor and combination regimes [ J ]. Clin Cardiol, 1995,18 (6) : 307-315.
  • 2Kuzuyama T. Mevalonate and nonmevalonate pathways for the biosynthesis of isoprene units [ J ]. Biosci Biotechnol Biochem, 2002, 66(8) : 1619 - 1627.
  • 3Turunen M, Olsson J, Dallner G, et al. Metabolism and function of coenzyme Q[ J]. Biochemica Biophysica Acta,2004, 1600(1-2): 171-199.
  • 4Goldstein JL, Brown MS. Regulation of the mevalonate pathway[J]. Nature, 1990, 343(6257) : 425 -430.
  • 5张雪玲,糜漫天,张乾勇,韦娜,李等松.Lovastatin对HL-60细胞HMG-CoA还原酶mRNA表达及细胞增殖功能的影响[J].第三军医大学学报,2004,26(1):39-42. 被引量:4
  • 6葛长江,胡申江.阿托伐他汀影响自发性高血压大鼠血压的机制探讨[J].中国病理生理杂志,2005,21(12):2324-2327. 被引量:15
  • 7Guijarro C, Blanco - Colio LM, Ortego M, et al. 3 - hydroxy- 3 -methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture[J]. Circ Res, 1998, 83(5) : 490- 500.
  • 8Flach J, Antoni I, Villemin P, et al. The mevalonate/isoprenoid pathway inhibitor apomine(SR - 4502.3A) is anti-proliferative and induces apoptosis similar to farnesol[ J ].Biochem Biophy Res Commun, 2000, 270 ( 1 ) : 240 -246.
  • 9Corsini A, Mazzoti M, Baited M, et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG - CoA reductase[J]. Atheroscleresis, 1993, 101(1): 117-125.
  • 10Bellosta S, Ferri N, Arnaboldi L, et al. Pleiotropic effects of stastins in artheroeclerosis and diabetes[ J]. Diabetes Care, 2000, 23(Suppl 2B) : 72 -78.

二级参考文献5

共引文献36

同被引文献38

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部